value investing | Multibagger Shares

May 22, 2026

Hero section introducing Chris Mayer’s 100-Bagger Framework with four quadrants labeled Trader, COMPOUNDER, Drift, and Speculator beneath the title.

Chris Mayer’s 100-Baggers Framework: The Seven Empirical Attributes Behind Every Hundred-Bagger Stock

Christopher Mayer's 365-stock empirical study extracted seven attributes that predicted 100x compounders. Titan Biotech FY25 illustrates five of the seven on a small-cap Indian balance sheet.

May 18, 2026

Hero header with title 'Buffett’s Four Filters' and subtitle, plus a two-by-two color grid: Trader (gray), COMPOUNDER (green), Drift (light gray), Speculator (orange).

Buffett’s Four Filters: The 1977 Berkshire Letter Acquisition Checklist Refined in the 1994 Owner’s Manual

Buffett's four filters — understandable business, favourable economics, able-and-trustworthy management, sensible price — applied step by step to Titan Biotech's FY25 audited numbers, in their canonical sequential order.

May 17, 2026

Infographic: The Klarman Doctrine title with a horizontal bar chart of FY20–FY25 values, ending with a green FY25 bar at 22.

The Klarman Doctrine: Seth Klarman’s 1991 ‘Margin of Safety’ Three-Pillar Architecture — Why Absolute Returns, Bottom-Up Bargain Hunting, and Risk Aversion Define the Real Value Investor’s Edge

Seth Klarman's 1991 'Margin of Safety' rebuilt value investing on three pillars: absolute returns, bottom-up bargain hunting, and risk aversion. How Titan Biotech FY25's audited numbers illustrate all three.

May 16, 2026

Hero section with title 'Look-Through Earnings' over a dark blue gradient, subtitle text, and a centered multicolor donut chart labeled 'FY25 Reinvested'.

Look-Through Earnings: Warren Buffett’s 1990 Berkshire Letter Framework for Measuring Your True Portfolio Earnings

Warren Buffett's 1990 Berkshire letter introduced look-through earnings — dividends plus your proportional share of retained profits. Why this single number reveals what your portfolio truly earned, illustrated by Titan Biotech FY25's high-retention, low-debt capex discipline.